Acute Services , Cancer Services and/or Radiotherapy Services , Community Services , Diagnostic, Screening and/or Pathology Services across Cheshire and Merseyside

The NHS Cheshire and Merseyside Integrated Care Board has awarded a contract for health services, including acute, cancer, radiotherapy, community, diagnostic, screening, and pathology services, across Cheshire and Merseyside. The procurement follows a Direct Award procedure under the Health Care Services (Provider Selection Regime) Regulations 2023 and falls outside the traditional Public Contracts Regulations 2015. The contract, valued at £39,325,000, commenced on 1st April 2025 and is set to expire on 31st March 2026.

The awarded supplier, Liverpool Heart and Chest Hospital NHS Foundation Trust, is tasked with delivering essential medical services to the region. The decision to award was made by the Finance, Investment, Resources Committee on 19th November 2024, following appropriate conflict of interest protocols. This procurement process opens significant opportunities for large healthcare service providers accustomed to high-value contracts and specialised health service delivery.

Businesses with expertise in providing diverse medical services, particularly in the areas of radiotherapy, screening, and pathology, stand well-placed to benefit. Companies capable of meeting stringent NHS standards and regulations without the typical competitive bidding due to the nature of Direct Awards might find similar future opportunities with the NHS Cheshire and Merseyside Integrated Care Board or within regions implementing similar procurement frameworks.